NCT00235235 - A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions

Breast Cancer

Interventions

PROCEDURE

Biopsy

core biopsy

PROCEDURE

Serum Collection

serum collection

PROCEDURE

Urine Collection

urine collection

DRUG

Doxorubicin

Doxorubicin 60 mg/m2 day 1 of every 21-day cycle

DRUG

Cyclophosphamide

Cyclophosphamide 600 mg/m2 day 1 of every 21-day cycle

DRUG

Capecitabine

Capecitabine 1000 mg/m2 bid days 1-14 of every 21-day cycle

DRUG

Vinorelbine

Vinorelbine 25mg/m2 days 1, 8, 15 of every 28-day cycle

DRUG

Gemcitabine

Gemcitabine 1000mg/m2 days 1, 8, 15 of every 28-day cycle

Trial Locations (11)

46202

Indiana University Cancer Center, Indianapolis

46227

Mary Lou Mayer, M.D., Indianapolis

46256

Community Regional Cancer Center, Indianapolis

46527

Center for Cancer Care at Goshen Health System, Goshen

46601

Northern Indiana Cancer Research Consortium, South Bend

46815

Fort Wayne Oncology & Hematology, Inc, Fort Wayne

47403

Cancer Care Center of Southern Indiana, Bloomington

47904

Arnett Cancer Care, Lafayette

47905

Horizon Oncology Center, Lafayette

77030

Baylor College of Medicine - Methodist Breast Center, Houston

Unknown

Instituto de Enfermedades Neoplasticas (INEN), Lima